At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 626 enrolled
Drug / intervention
Fluticasone propionate +1 moredrug
Likely dose
Fluticasone propionate 200 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy of Once-Daily Fluticasone Propionate Aqueous Nasal Spray 200mcg for 14 Days on Ocular Symptoms Associated With Seasonal Allergic Rhinitis
In Brief
A Phase 3 clinical trial evaluating Fluticasone propionate and Placebo for Allergic Rhinitis and Seasonal Allergic Rhinitis. Completed, enrolled 626 participants across 1 site.
Detailed Summary
This study is designed to investigate the efficacy of fluticasone propionate (FP) on ocular symptoms associated with allergic rhinitis (AR).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Rhinitis, Seasonal Allergic Rhinitis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2012
Primary CompletionFeb 2013
First PostedMar 2013
TodayJul 2026
First PostedMar 25, 2013
Enrollment StartDec 1, 2012
Primary CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 13.3 years ago
Interventions
Fluticasone propionatedrug
Nasal spray formulation (200 mcg/day)
Placebodrug
Vehicle for Fluticasone propionate aqueous nasal spray